Shanghai Bao Pharmaceuticals Co., Ltd. logo

Shanghai Bao Pharmaceuticals Co., Ltd.

2659.HK

HKSEHealthcareBiotechnology

最新数据

HK$15.73

−HK$0.36 · -2.24%

8月24日 16:08 HKT

2659.HK公司概览

盘中时间采用HKT。市场数据可能有所延迟。

公司概况

公司网站

Shanghai Bao Pharmaceuticals Co., Ltd., a biotechnology company, engages in the research, development, and commercialization of pharmaceutical products in Mainland China. The company uses synthetic biology technology to develop and deliver recombinant biologic drugs. Its products include KJ017, a recombinant human hyaluronidase for subcutaneous drug delivery; KJ103, a recombinant immunoglobulin G (IgG)-degrading enzyme for IgG-mediated autoimmune diseases; and SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH CTP) for assisted reproduction. The company also develops KJ101, a recombinant human chymotrypsin developed through synthetic biology that is in Phase 2 clinical trials; KJ015, a bispecific anti HER2 antibody; BJ007, a subcutaneous formulation of ceftriaxone sodium for the treatment of bacterial infections; BJ009, a first generation cephalosporin antibiotic for treating bacterial infections, including of the skin, bones, joints, reproductive organs, blood, heart valves, respiratory tract, biliary tract, and urinary tract; and SJ04, a recombinant human chorionic gonadotropin (hCG) that can be used in assisted reproductive procedures to accelerate follicle maturation and induce ovulation. These product candidates are in Phase 1 clinical trials. In addition, it is developing BJ045, a subcutaneously administered anti CD20 antibody; BJ047, a subcutaneously administered anti CD154 antibody; BJ008, a subcutaneous formulation of cefoperazone sodium–sulbactam sodium to treat bacterial infections; and BJ044, a serine protease inhibitor with broad anti inflammatory properties. These product candidates are in the preclinical stage. Further, the company licenses its intellectual property and other deliverables and provides technical services. Shanghai Bao Pharmaceuticals Co., Ltd. was founded in 2019 and is based in Shanghai, China.

行业
Biotechnology
部门
Healthcare
总部
CN
首席执行官
Wang Zheng
上市以来
2025年12月10日
雇员
354

市场位置

日内区间

当前HK$15.73,

52周区间

当前HK$15.73,

开盘价
HK$16.12
前收盘价
HK$16.09
成交量
20.11万
0.08× 平均值
平均成交量
266.66万
日均成交量
市值
24.02亿 HKD
贝塔
0.92
市场参考 1
50天平均值
HK$17.9348
低于平均水平-12.29%
200天平均值
HK$67.3497
低于平均水平-76.64%

2659.HK同业公司

持有2659.HK的ETF

报告持有此股票敞口的交易所交易基金。

继续GoAI的研究

在 GoAI 中研究2659.HK

research.disclaimer